Tillotts Pharma
Switzerland - Rheinfelden
PharmaceuticalFocus: Small Molecules, Specialty Pharma
Tillotts Pharma is a life sciences company focused on Small Molecules, Specialty Pharma.
ImmunologyGastroenterology
Employees
201-500
Open Jobs
0
Pipeline & Clinical Trials
TP05 Coating A
Ulcerative ColitisClinical Trials (1)
NCT02306772TP0501 - Pharmaco-Scintigraphic-Study
Phase 1TP05 Coating D
Ulcerative ColitisClinical Trials (1)
NCT02306785TP0502-Pharmaco-Scintigraphic-Study and Amendment
Phase 1Metronidazole Benzoate gastro-resistant capsule with radio-labelled mucoadhesive formulation
HealthyClinical Trials (1)
NCT02911298Pharmaco-Scintigraphic Study to Evaluate the Release Profile of Metronidazole Benzoate Capsules
Phase 1Phase 1
Clinical Trials (1)
NCT02306798TP0502-B-Pharmaco-Scintigraphic-Study
Phase 1Mesalazine
Irritable Bowel SyndromeClinical Trials (1)
NCT01699438Mesalazine Treatment in IBS (The MIBS Study)
Phase 2Phase 3
Clinical Trials (1)
NCT01903252TP05 for the Treatment of Mild to Moderate Active Ulcerative Colitis (UC)
Phase 3Epanova™
Crohn's DiseaseClinical Trials (1)
NCT00074542An Efficacy and Safety Study of Omega-3 Free Fatty Acids (Epanova™) for the Maintenance of Symptomatic Remission in Subjects With Crohn's Disease
Phase 3Phase 3
Clinical Trials (1)
NCT01257399Comparative Efficacy and Safety Study in Patients With Ulcerative Colitis in Remission Phase
Phase 3Asacol®
Active Ulcerative ColitisClinical Trials (1)
NCT01257386Comparative Efficacy and Safety Study in Patients With Active Ulcerative Colitis
Phase 3Epanova
Crohn's DiseaseClinical Trials (1)
NCT00613197EPANOVA in Crohn's Disease, Study 1
Phase 3Mesalamin
Ulcerative ColitisClinical Trials (1)
NCT01059344Efficacy and Safety of Asacol™ 4.8 g/Day (800 mg Tablets) for the Treatment of Active Ulcerative Colitis
Phase 3Phase 4
Clinical Trials (1)
NCT02190526Effects of Mesalamine and Amitriptyline on Irritable Bowel Syndrome
Phase 4Open Jobs (0)
No open positions listed yet. Check their careers page directly.
Interview Prep Quick Facts
Founded: 2009
Portfolio: 12 clinical trials